Dataset Information

Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.

ABSTRACT: Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a strong predictor of relapse, with individuals receiving high doses of cyclophosphamide or ifosphamide having only one very late molecularly confirmed relapse (p = 0.032). The anatomical location of recurrence is metastatic in 12 of 15 relapses, with 8 of 12 metastatic relapses in the lateral ventricles. Maintenance chemotherapy, specifically cumulative cyclophosphamide doses, is a significant predictor of relapse across WNT MB. Future efforts to de-escalate therapy need to carefully consider not only the radiation dose but also the chemotherapy regimen and the propensity for metastatic relapses.

SUBMITTER: Nobre L

PROVIDER: S-EPMC7394286 | biostudies-literature | 2020 Jun

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.

Nobre Liana L Zapotocky Michal M Khan Sara S Fukuoka Kohei K Fonseca Adriana A McKeown Tara T Sumerauer David D Vicha Ales A Grajkowska Wieslawa A WA Trubicka Joanna J Li Kay Ka Wai KKW Ng Ho-Keung HK Massimi Luca L Lee Ji Yeoun JY Kim Seung-Ki SK Zelcer Shayna S Vasiljevic Alexandre A Faure-Conter Cécile C Hauser Peter P Lach Boleslaw B van Veelen-Vincent Marie-Lise ML French Pim J PJ Van Meir Erwin G EG Weiss William A WA Gupta Nalin N Pollack Ian F IF Hamilton Ronald L RL Nageswara Rao Amulya A AA Giannini Caterina C Rubin Joshua B JB Moore Andrew S AS Chambless Lola B LB Vibhakar Rajeev R Ra Young Shin YS Massimino Maura M McLendon Roger E RE Wheeler Helen H Zollo Massimo M Ferruci Veronica V Kumabe Toshihiro T Faria Claudia C CC Sterba Jaroslav J Jung Shin S López-Aguilar Enrique E Mora Jaume J Carlotti Carlos G CG Olson James M JM Leary Sarah S Cain Jason J Krskova Lenka L Zamecnik Josef J Hawkins Cynthia E CE Tabori Uri U Huang Annie A Bartels Ute U Northcott Paul A PA Taylor Michael D MD Yip Stephen S Hansford Jordan R JR Bouffet Eric E Ramaswamy Vijay V

Cell reports. Medicine 20200601 3

Over the past decade, wingless-activated (WNT) medulloblastoma has been identified as a candidate for therapy de-escalation based on excellent survival; however, a paucity of relapses has precluded additional analyses of markers of relapse. To address this gap in knowledge, an international cohort of 93 molecularly confirmed WNT MB was assembled, where 5-year progression-free survival is 0.84 (95%, 0.763-0.925) with 15 relapsed individuals identified. Maintenance chemotherapy is identified as a ...[more]

PMID: 32743560

Similar Datasets

Project description:Medulloblastoma is heterogeneous, being characterized by molecular subgroups that demonstrate distinct gene expression profiles. Activation of the WNT or SHH signaling pathway characterizes two of these molecular subgroups, the former associated with low-risk disease and the latter potentially targeted by novel SHH pathway inhibitors. This manuscript reports the validation of a novel diagnostic immunohistochemical method to distinguish SHH, WNT, and non-SHH/WNT tumors and details their associations with clinical, pathological and cytogenetic variables. A cohort (n = 235) of medulloblastomas from patients aged 0.4-52 years was studied for expression of four immunohistochemical markers: GAB1, β-catenin, filamin A, and YAP1. Immunoreactivity (IR) for GAB1 characterizes only SHH tumors and nuclear IR for β-catenin only WNT tumors. IRs for filamin A and YAP1 identify SHH and WNT tumors. SHH, WNT, and non-SHH/WNT tumors contributed 31, 14, and 55% to the series. All desmoplastic/nodular (D/N) medulloblastomas were SHH tumors, while most WNT tumors (94%) had a classic phenotype. Monosomy 6 was strongly associated with WNT tumors, while PTCH1 loss occurred almost exclusively among SHH tumors. MYC or MYCN amplification and chromosome 17 imbalance occurred predominantly among non-SHH/WNT tumors. Among patients aged 3-16 years and entered onto the SIOP PNET3 trial, outcome was significantly better for children with WNT tumors, when compared to SHH or non-SHH/WNT tumors, which showed similar survival curves. However, high-risk factors (M+ disease, LC/A pathology, MYC amplification) significantly influenced survival in both SHH and non-SHH/WNT groups. We describe a robust method for detecting SHH, WNT, and non-SHH/WNT molecular subgroups in formalin-fixed medulloblastoma samples. In corroborating other studies that indicate the value of combining clinical, pathological, and molecular variables in therapeutic stratification schemes for medulloblastoma, we also provide the first outcome data based on a clinical trial cohort and novel data on how molecular subgroups are distributed across the range of disease.

Dataset Information

Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.

Publications

Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets